Tan W, Irie K, McIntire C, Torres J, Jones R, Gibson A
Antimicrob Agents Chemother. 2025; 69(3):e0122724.
PMID: 39912647
PMC: 11881557.
DOI: 10.1128/aac.01227-24.
Dong Q, Chen Z, Boland J, Dokos C, Hagos Y, Kuhne A
Clin Transl Sci. 2025; 18(2):e70141.
PMID: 39895366
PMC: 11788587.
DOI: 10.1111/cts.70141.
Mahar K, van Noort M, van den Berg P, Yang S, Visser S, Post T
Clin Pharmacol Ther. 2025; 117(3):846-856.
PMID: 39876087
PMC: 11835430.
DOI: 10.1002/cpt.3544.
Tong D, Hughes M, Hu J, Pearson J, Kubiak D, Dionne B
Antimicrob Agents Chemother. 2025; 69(2):e0104024.
PMID: 39791873
PMC: 11823644.
DOI: 10.1128/aac.01040-24.
Garraza-Obaldia M, Jaramillo S, Parra-Guillen Z, Valencia J, Gambus P, Troconiz I
Pharmaceutics. 2025; 16(12.
PMID: 39771593
PMC: 11677492.
DOI: 10.3390/pharmaceutics16121615.
Dynamics of thrombin generation: Filling the gap between the system pharmacology theory and clinical practice in clinical pharmacology and therapeutics.
Ruiz L, Jaramillo S, Calvo A, Torrente M, Tassies D, Reverter J
Pharmacol Res Perspect. 2024; 13(1):e70014.
PMID: 39739766
PMC: 11687557.
DOI: 10.1002/prp2.70014.
Population Pharmacokinetic and Toxicity Analysis of High-Dose Methotrexate in Patients with Central Nervous System Lymphoma.
Yin A, de Groot F, Guchelaar H, Nijland M, Doorduijn J, Touw D
Clin Pharmacokinet. 2024; 64(1):79-91.
PMID: 39625585
DOI: 10.1007/s40262-024-01452-6.
Population pharmacokinetics of rilpivirine following oral administration and long-acting intramuscular injection in real-world people with HIV.
Thoueille P, Saldanha S, Schaller F, Choong E, Veuve F, Munting A
Front Pharmacol. 2024; 15:1437400.
PMID: 39619609
PMC: 11605395.
DOI: 10.3389/fphar.2024.1437400.
Population pharmacokinetic analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemia.
Vaddady P, Glatard A, Smania G, Nakayama S, Inoue H, Kurumaddali A
Clin Transl Sci. 2024; 17(12):e70074.
PMID: 39601658
PMC: 11600623.
DOI: 10.1111/cts.70074.
Exposure-response modeling of liver fat imaging endpoints in non-alcoholic fatty liver disease populations administered ervogastat alone and co-administered with clesacostat.
Hughes J, Amin N, Wojciechowski J, Vourvahis M
CPT Pharmacometrics Syst Pharmacol. 2024; 14(2):317-330.
PMID: 39564924
PMC: 11812935.
DOI: 10.1002/psp4.13275.
Concentration-QTcF analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemia.
Vaddady P, Smania G, Nakayama S, Inoue H, Kurumaddali A, AbuTarif M
Clin Transl Sci. 2024; 17(11):e70065.
PMID: 39533519
PMC: 11557512.
DOI: 10.1111/cts.70065.
Population pharmacokinetic modeling of paired plasma-breast milk lamivudine data for estimation of infant exposure in breastfeeding mother-infant pairs.
Ojara F, Kawuma A, Nakalema S, Kyohairwe I, Nakijoba R, Lamorde M
CPT Pharmacometrics Syst Pharmacol. 2024; 13(11):1978-1989.
PMID: 39508333
PMC: 11578128.
DOI: 10.1002/psp4.13274.
Population Pharmacokinetic Quantification of CYP2D6 Activity in Codeine Metabolism in Ambulatory Surgical Patients for Model-Informed Precision Dosing.
Ashraf M, Poikola S, Neuvonen M, Kiiski J, Kontinen V, Olkkola K
Clin Pharmacokinet. 2024; 63(11):1547-1560.
PMID: 39441506
PMC: 11573879.
DOI: 10.1007/s40262-024-01433-9.
Exposure-Efficacy Analysis and Dopamine D2 Receptor Occupancy in Adults with Schizophrenia after Treatment with the Monthly Intramuscular Injectable Risperidone ISM.
Lindauer A, Snoeck E, Laveille C, Ayani I, de Monasterioguren L, Almendros M
J Clin Pharmacol. 2024; 65(3):350-360.
PMID: 39417209
PMC: 11867924.
DOI: 10.1002/jcph.6152.
Target-site cefiderocol pharmacokinetics in soft tissues of healthy volunteers.
Sanz-Codina M, van Os W, Pham A, Jorda A, Wolf-Duchek M, Bergmann F
J Antimicrob Chemother. 2024; 79(12):3281-3288.
PMID: 39373642
PMC: 11638555.
DOI: 10.1093/jac/dkae359.
Model-based translation of results from in vitro to in vivo experiments for afabicin activity against Staphylococcus aureus.
Saporta R, Nielsen E, Menetrey A, Cameron D, Nicolas-Metral V, Friberg L
J Antimicrob Chemother. 2024; 79(12):3150-3159.
PMID: 39315768
PMC: 11638087.
DOI: 10.1093/jac/dkae334.
Model informed dose regimen optimizing in development of leritrelvir for the treatment of mild or moderate COVID-19.
Wang K, Li H, Li Y, Xu F, Sun Z, Yang Y
Front Pharmacol. 2024; 15:1449583.
PMID: 39263567
PMC: 11387175.
DOI: 10.3389/fphar.2024.1449583.
Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia.
Mahar K, Yang S, Mesic E, Post T, Goulooze S
Clin Pharmacokinet. 2024; 63(9):1327-1341.
PMID: 39259485
DOI: 10.1007/s40262-024-01417-9.
A model-based approach using GSK3772847, an anti-interleukin-33 receptor monoclonal antibody, as a showcase to predict SC administration PK and free target dynamics based on PK and total target measurements after IV administration.
Berkhout J, Fairman D, van Noort M, van Steeg T
CPT Pharmacometrics Syst Pharmacol. 2024; 14(1):17-27.
PMID: 39258338
PMC: 11706423.
DOI: 10.1002/psp4.13234.
Population PK modeling of certolizumab pegol in pregnant women with chronic inflammatory diseases.
Menshykau D, Sidhu J, Shaughnessy L, Lledo-Garcia R, Dua P, Teil M
CPT Pharmacometrics Syst Pharmacol. 2024; 13(11):1904-1914.
PMID: 39219320
PMC: 11578139.
DOI: 10.1002/psp4.13220.